Valuation: NetraMark Holdings Inc.

Market Cap 62.45M 44.88M 38.87M 36.76M 33.28M 4.3B 62.92M 439M 169M 2.18B 169M 165M 6.96B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 62.45M 44.88M 38.87M 36.76M 33.28M 4.3B 62.92M 439M 169M 2.18B 169M 165M 6.96B EV / Sales 2026 *
156x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 week-5.71%
Current month+3.12%
1 month-2.94%
3 months-15.38%
6 months-35.92%
Current year-40.00%
1 week 0.66
Extreme 0.66
0.7
1 month 0.6
Extreme 0.6
0.75
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.65
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Tax

General Counsel

6,944 0.0075%
9/1/26 A Other

Director

0 0%
9/1/26 A Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.71%-55.70%+144.44% 44.88M
-1.64%+0.64%-3.54%+50.54% 3,691B
-0.43%+1.33%+0.79%+1,025.64% 415B
+0.10%+9.53%+66.08%+143.54% 82.68B
-1.83%-3.57%-22.06%+17.04% 75.45B
-3.60%-6.21%-12.29%-18.64% 70.46B
-5.55%-9.42%-46.10%+161.33% 62.87B
-1.54%+7.59%+9.17%-6.51% 48.05B
-4.93%-0.65%-14.29%+48.28% 39.62B
-2.05%+12.09%-63.40%+80.01% 35.89B
Average -0.35%+1.38%-14.13%+164.57% 452.11B
Weighted average by Cap. -0.46%+1.14%-3.34%+141.19%

Financials

2026 *2027 *
Net sales 401K 288K 250K 236K 214K 27.63M 404K 2.82M 1.08M 14.01M 1.08M 1.06M 44.69M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
15/09/26 CA$0.6600 0.00% 5,265
14/09/26 CA$0.6600 -2.94% 12,100
11/09/26 CA$0.6800 -2.86% 30,120
10/09/26 CA$0.7000 0.00% 19,493
09/09/26 CA$0.7000 0.00% 9,675

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!